NCT04155203View on ClinicalTrials.gov

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

PHASE3CompletedINTERVENTIONAL
Enrollment

657

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions
Secondarily Infected Traumatic Skin Lesions
Interventions
DRUG

Mupirocin Calcium

mupirocin cream

DRUG

Mupirocin Calcium

Reference mupirocin cream

DRUG

Vehicle

vehicle control cream

Trial Locations (1)

33409

Palm Beach Research Center, West Palm Beach

Sponsors

Lead Sponsor

Padagis LLC
All Listed Sponsors
lead

Padagis LLC

INDUSTRY

NCT04155203 - To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions | Biotech Hunter | Biotech Hunter